NPM1 and myeloid neoplasm: This change resulted in an increase in the diagnosis of certain subtypes (such as AML with NPM1 and FLT3-ITD mutations), while other subtypes (such as AML with bone marrow proliferative abnormalities and treatment-related myeloid neoplasms) gained new recognition [40].